Chalazion

Chalazion

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Chalazion is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • Meibomian Cyst
  • Tarsal Cyst

Disorder Subdivisions

  • None

General Discussion

Chalazion is a round, slowly emerging, localized swelling, in the form of a cyst located on the lower or upper eyelid. (Chalazion is the Greek word for "hailstone" which represents the size of the lump that makes up the cyst.) The usually painless, grainy (granulomatous) mass is due to inflammation, obstruction, and retained secretions of one of the glands that lubricates the edge of the eyelids. These glands secrete sebum, an oily, protective fluid. If one or more of the ducts that drain these glands is blocked, the sebum accumulates under the skin to form a cyst.



In rare cases, if the cyst is large, blurred vision may result due to pressure on the cornea, the front, clear portion of the eye through which light passes. In some affected individuals, chalazia may disappear spontaneously. However, in other cases, treatment may be required. Individuals with chronic inflammation of the eyelids (blepharitis) may be prone to recurrences.

Symptoms

Chalazion is a chronic inflammation of the meibomian gland, a gland of the eyelids that secretes an oily, protective fluid. It is characterized by an irritation and swelling of the eyelid. There may be a small, round, moveable swelling of the meibomian gland. The inflammation is usually painless unless it enlarges and causes an inflammation of the eyelids' membrane (conjunctiva). Chalazion tends to occur more often on he upper eyelid than on the lower eyelid.

Causes

The exact cause of chalazion is not known. It is thought to be caused by a blockage of the duct of the oil-producing meibomian gland. When oil cannot flow through the duct, it accumulates, resulting in a lump on the eyelid. Unlike styes, which form on the edge of the eyelids, chalazia are not the result of bacterial infection.

Affected Populations

Chalazion affects males and females in equal numbers.

Standard Therapies

Chalazia will often subside after a few months. The application of hot compresses, and topical antibiotic ointments such as bacitracin and erythromycin, may be effective. If necessary, surgical removal can be done under local anesthesia, usually in an ophthalmologist's office. The healing process may require wearing an eye patch for about a day.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.



For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:



Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov



For information about clinical trials sponsored by private sources, contact:

www.centerwatch.com

References

TEXTBOOKS

Beers MH, Berkow R., eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:710.



Berkow R., ed. The Merck Manual-Home Edition.2nd ed. Whitehouse Station, NJ: Merck Research Laboratories; 2003:1295.



JOURNAL ARTICLES

Dhaliwal U, Arora VK, Singh N, et al. Cytopathology of chalazia. Diagn Cytopathol. 2004;31.



D'hermies F, Fayet B, Meyer A. [Chalazion mimicking an eyelid tumor.] J Fr Ophthalmol. 2004;27:202-05. French.



Ozdal PC, Cordere F, Callejo S, et al. Accuracy of the clinical diagnosis of chalazion. Eye. 2004;18:135-38.



Shiramizu KM, Kreiger AE, McCannel CA. Severe visual loss caused by ocular perforation during chalazion removal. Am J Ophthalmol. 2004;137:204-05.



Ho SY, Lai JS. Subcutaneous steroid injection as treatment for chalazion: prospective case series. Hong Kong Med J. 2002;8:18-20.



Mustafa TA, Oriafage IH. Three methods of treatment of chalazia in children. Saudi Med J. 2001;22:968-72.



Jackson TL, Beun L. A prospective study of cost, patient satisfaction, and outcome of treatment of chalazion by medical and nursing staff. Br J Ophthalmol. 2000;84:782-85.



FROM THE INTERNET

Douglas RS. Medical Encyclopedia: Chalazion. MedlinePlus. Update Date: 12/22/2002. 2pp.

www.nlm.nih.gov/medlineplus/ency/article/001006.htm

Resources

Schepens Eye Research Institute

20 Staniford Street

Boston, MA 02114-2500

Tel: (617)912-0100

Fax: (617)912-0101

Email: richard.godfrey@schepens.harvard.edu

Internet: http://www.theschepens.org/



NIH/National Eye Institute

31 Center Dr

MSC 2510

Bethesda, MD 20892-2510

United States

Tel: (301)496-5248

Fax: (301)402-1065

Email: 2020@nei.nih.gov

Internet: http://www.nei.nih.gov/



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.